Lipid-induced colonic hypersensitivity in irritable bowel syndrome: The role of 5-HT3 receptors

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 279-287

  Simren M ^a   Simms, L ^b   D'Souza, D ^b   Abrahamsson, H ^a   Bjornsson E S ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTINEOPLASTIC AGENT; GRANISETRON; LIPID; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TAUROSELCHOLIC ACID SE 75;

ADULT; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON DILATATION; COLON DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; FEMALE; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; BALLOON DILATATION; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; CROSS-OVER STUDIES; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY; LIPIDS; MIDDLE AGED; PRESSURE; RECEPTORS, SEROTONIN; SENSATION; SENSORY THRESHOLDS; SEROTONIN ANTAGONISTS;

EID: 0037316960     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01399.x     Document Type: Article

References (31)

1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
2. Agreus L, Svärdsudd K. Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
3. Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001: 63: 108-15.
4. Narducci F, Bassotti G, Granata MT, et al. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide, Dig Dis Sci 1986; 31; 241-6.
5. Sullivan MA, Cohen S, Snape WJ Jr. Colonic myoelectrical activity in irritable bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978: 298: 878-83.
6. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001: 48: 20-7.
7. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tone and phasic responses in humans. Gut 1994: 35: 536-41.
8. Björnsson ES, Chey WD, Ladabaum U, et al. Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol 1998: 275: G498-505.
9. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998: 42: 42-6.
10. Camilleri M. Mayer EA, Drossman DA. et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999: 13: 1149-59.
11. Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999: 13(Suppl. 2): 31-8.
12. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998: 12: 849-55.
13. Houghton LA, Foster JM, Whorwell PJ, Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000: 14: 775-82.
14. Thumshirn M, Coulie B, Camilleri M, et al. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000: 14: 869-78.
15. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998: 274: G584-90.
16. Whitehead WE, Delvaux M. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. Dig Dis Sci 1997: 42: 223-41.
17. Jones RH, Holtmann G, Rodrigo L. et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999: 13: 1419-27.
18. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993: 7: 175-80.
19. Zighelboim J, Talley NJ, Phillips SE, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995: 40: 819-27.
20. Hammer J, Phillips SF, Talley NJ, Camilleri M. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993: 7: 543-51.
21. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996: 57: 478-83.
22. Simrén M, Castedal M, Svedlund J, Abrahamsson H. Björnsson E. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS). Dig Dis Sci 2000; 45: 2151-61.
23. Munakata J, Naliboff B. Harraf F. et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997: 112: 55-63.
24. Simrén M, Ringström G, Björnsson E, Abrahamsson H. Hypnotherapy reduces lipid-induced colonic hypersensitivity in the irritable bowel syndrome (IBS). Gastroenterology 2002: 122: A69.
25. Roberts-Thomson IC, Fettman MJ, Jonsson JR, Frewin DB. Responses to cholecystokinin octapeptide in patients with functional abdominal pain syndromes. J Gastroenterol Hepatol 1992: 7: 293-7.
26. Elsenbruch S, Orr WC. Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol 2001: 96: 460-6.
27. Ford MJ, Camilleri M, Wiste JA, Hanson RB. Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon. Gut 1995: 37: 264-9.
28. Azpiroz F, Malagelada JR. Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 1985: 248: G229-37.
29. Friedel D. Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology 2001: 120: 557-60.
30. Thompson CA. Alosetron withdrawn from market. Am J Health Syst Pharm 2001: 58: 13.
31. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000: 18: 163-73.